The Latest Hepatology Medical Journal Articles

Keep up to date with the latest in hepatology as a sub-specialty of gastroenterology. Check out the latest hepatology articles from leading medical journals in a single view, helping you discover relevant articles quickly and easily.

• Common mental disorders in irritable bowel syndrome: pathophysiology, management, and considerations for future randomised controlled trials.15th February 2021
  The frequent co-occurrence of irritable bowel syndrome and the common mental disorders of anxiety and depression is well established. A range of biological and psychosocial disease mechanisms are common to both disorders, many of which contribute to a dysregulated gut-brain axis. Clinical and subthreshold psychological comorbidity adds to the functional impairment and disease burden in […]
• Transient Elastography Accurately Screens for Compensated Advanced Chronic Liver Disease in Patients with Ongoing or Recent Alcohol Withdrawal.15th February 2021
  Liver stiffness measurement by transient elastography (TE) is a promising method for staging fibrosis in alcohol-related liver disease, but uncertainties remain regarding the influence of alcohol consumption and thus the ideal timing for TE performance. We evaluated the performance of TE compared with liver biopsy to exclude compensated advanced chronic liver disease (cACLD) in patients […]
• Prevention and treatment of nutritional complications after bariatric surgery.14th February 2021
  Obesity and the corresponding burden of related diseases is a major public health issue worldwide that is reaching pandemic proportions. Bariatric surgery is the only intervention that has been shown to result in substantial and lasting weight loss, and a decrease in overall mortality for patients with severe obesity. Consequently, the population of patients having […]
• Adaptations in gastrointestinal physiology after sleeve gastrectomy and Roux-en-Y gastric bypass.14th February 2021
  Linked to the growing obesity epidemic, demand for bariatric and metabolic surgery has increased, the most common procedures being sleeve gastrectomy and Roux-en-Y gastric bypass. Originally, bariatric procedures were described as purely restrictive, malabsorptive, or combined restrictive-malabsorptive procedures limiting food intake, nutrient absorption, or both. Nowadays, anatomical alterations are known to affect gastrointestinal physiology, which […]
• Antiviral therapy in the palliative setting of HCC (BCLC B and C).14th February 2021
  The potential impact of direct-acting antivirals (DAAs) in patients with Barcelona Clinic Liver Cancer (BCLC)-B/C hepatocellular carcinoma (HCC) is understudied. HCC patients have been systematically excluded from randomised controlled trials evaluating the effectiveness of DAAs. Thus, the benefits of DAAs in patients with HCC are less defined. The presence of active HCC before initiating DAA […]
• UTILITY AND COST-EFFECTIVENESS OF A NON-ENDOSCOPIC APPROACH TO BARRETT’S ESOPHAGUS SURVEILLANCE AFTER ENDOSCOPIC THERAPY.13th February 2021
  A non-endoscopic approach to Barrett’s esophagus (BE) surveillance after radiofrequency ablation (RFA) would offer a less invasive method for monitoring. We assessed the test characteristics and cost-effectiveness of the Cytosponge® in post-RFA patients.We performed a multicenter study of dysplastic BE patients after at least one round of RFA. A positive Cytosponge® before endoscopy was defined […]
• A structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitis.13th February 2021
  Farnesoid X receptor (FXR) agonists have been validated to benefit patients with nonalcoholic steatohepatitis (NASH), although improvements in efficacy and/or tolerability remain elusive.In this 12-week, randomized, placebo (PBO)-controlled study, we evaluated MET409 – a non-bile acid agonist with a unique chemical scaffold – in three cohorts of subjects with NASH: 80 mg (n=20), 50 mg […]
• Diagnosis and management of secondary causes of steatohepatitis.12th February 2021
  The term non-alcoholic liver disease (NAFLD) was originally coined to describe hepatic fat deposition as part of the metabolic syndrome. However, a variety of rare hereditary liver and metabolic diseases, intestinal diseases, endocrine disorders and drugs may cause hepatic steatosis reminiscent of NAFLD, aggravate obesity-/metabolic syndrome-associated lipid deposition, or coexist with NAFLD. In contrast to […]
• TBX3 functions as a tumor suppressor downstream of activated CTNNB1 mutants during hepatocarcinogenesis.12th February 2021
  Gain of function (GOF) mutation of CTNNB1 gene is one of the most frequent genetic events in hepatocellular carcinoma (HCC). T-box transcription factor 3 (TBX3) is a liver-specific target of the Wnt/β-Catenin pathway and thought to be an oncogene mediating activated β-Catenin driven HCC formation.We evaluated TBX3 expression pattern in human HCC specimens. Tbx3 was […]
• Established and novel therapeutic options for autoimmune hepatitis.11th February 2021
  Autoimmune hepatitis is an immune-mediated disorder characterised by hypergammaglobulinaemia, autoantibodies, and interface hepatitis. The mainstay of treatment is non-specific immunosuppression, consisting of steroids with or without azathioprine. Although most patients respond satisfactorily to steroid and thiopurine-based treatment regimens, up to 40% relapse and 10% undergo liver transplantation. The cause of autoimmune hepatitis is unknown, but […]
• Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH.11th February 2021
  Perturbations of intracellular magnesium (Mg2+) homeostasis have implications for cell physiology. The cyclin M family, CNNM, perform key functions in the transport of Mg2+ across cell membranes.Clinical characterization of serum Mg2+ levels and hepatic CNNM4 expression. Primary hepatocytes cultured under methionine and choline deprivation. In vivo rodent NASH models: 0.1% methionine and choline-deficient and choline-deficient […]
• Risk of cancer in biopsy-proven alcohol-related liver disease: A population-based cohort study of 3,410 persons.9th January 2021
  Persons with alcohol-related liver disease (ALD) are at an increased risk of death and liver-related endpoints, but the association with incident cancer is not well understood, and whether it differs across histopathological subgroups is undefined.We investigated the risk of cancer in 3,410 persons with a diagnosis of ALD and an available liver biopsy in Sweden […]
• Frequency of Bowel Movements and Risk of Diverticulitis.8th January 2021
  The etiology of diverticulitis is poorly understood. The long-held belief that constipation and low-fiber diet are risk factors for diverticulosis has recently been challenged by studies that suggest that more frequent bowel movements predispose to diverticulosis. We aim to prospectively explore the association between bowel movement frequency and incident diverticulitis.We studied participants of the Nurses’ […]
• Obesity, Type 2 Diabetes, Lifestyle Factors and Risk of Gallstone Disease: A Mendelian Randomization Investigation.8th January 2021
  Obesity, type 2 diabetes, and lifestyle factors (cigarette smoking, alcohol drinking, and coffee consumption) have been associated with the risk of developing gallstone disease in observational studies, but whether these associations are causal is undetermined. We conducted a Mendelian randomization study to assess these associations.Genetic instruments associated with the exposures at the genome-wide significance (p<5×10-8) […]
• Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402).8th January 2021
  This study aimed to assess the efficacy of the combination of nivolumab (nivo) plus ipilimumab (ipi) as a first-line therapy with respect to the 12-month overall survival (OS) in patients with metastatic uveal melanoma (MUM) who are not eligible for liver resection.This was a single-arm, phase II trial led by the Spanish Multidisciplinary Melanoma Group […]
• Phase III Randomized Controlled Trial of eRAPID: eHealth Intervention During Chemotherapy.8th January 2021
  Electronic patient self-Reporting of Adverse-events: Patient Information and aDvice (eRAPID) is an online eHealth system for patients to self-report symptoms during cancer treatment. It provides automated severity-dependent patient advice guiding self-management or medical contact and displays the reports in electronic patient records. This trial evaluated the impact of eRAPID on symptom control, healthcare use, patient […]
• Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment.7th January 2021
  Data regarding the real-world effectiveness and safety of sofosbuvir/velpatasvir (SOF/VEL) with or without low-dose ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) infection and severe renal impairment (RI) are limited. We evaluated the performance of SOF/VEL with or without low-dose RBV in HCV-infected patients with chronic kidney disease stage 4 or 5.191 patients […]
• Whole exome HBV DNA integration is independent of the intrahepatic HBV reservoir in HBeAg-negative chronic hepatitis B.6th January 2021
  The involvement of HBV DNA integration in promoting hepatocarcinogenesis and the extent to which the intrahepatic HBV reservoir modulates liver disease progression remains poorly understood. We examined the intrahepatic HBV reservoir, the occurrence of HBV DNA integration and its impact on the hepatocyte transcriptome in hepatitis B ‘e’ antigen (HBeAg)-negative chronic hepatitis B (CHB).Liver tissue […]
• Colonic epithelial-derived Selenoprotein P is the source for antioxidant-mediated protection in colitis-associated cancer.3rd January 2021
  Patients with inflammatory bowel disease (IBD) demonstrate nutritional selenium deficiencies and are at greater risk for colon cancer. Previously, we determined that global reduction of the secreted antioxidant selenium-containing protein, Selenoprotein P (SELENOP), substantially increased tumor development in an experimental colitis-associated cancer (CAC) model. We next sought to delineate tissue-specific contributions of SELENOP to intestinal […]
• Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: a prospective, registry-based, single-arm, observational, evaluation study.2nd January 2021
  Stereotactic ablative body radiotherapy (SABR) is increasingly being used to treat oligometastatic cancers, but high-level evidence to provide a basis for policy making is scarce. Additional evidence from a real-world setting is required. We present the results of a national study of patients with extracranial oligometastases undergoing SABR, representing the largest dataset, to our knowledge, […]
• The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease related genetic variants.2nd January 2021
  Metabolic dysfunction-associated fatty liver disease (MAFLD) is a newly proposed disease category that derived from non-alcoholic fatty liver disease. The impact of MAFLD on health events has not been investigated.UK Biobank participants were diagnosed for whether MAFLD presented at baseline. Five genetic variants (PNPLA3 rs738409 C/G, TM6SF2 rs58542926 C/T, GCKR rs1260326 T/C, MBOAT7 rs641738 C/T, […]
• Racial and Ethnic Disparities in Survival Among Patients with Hepatocellular Carcinoma in the United States: A Systematic Review and Meta-Analysis.2nd January 2021
  Hepatocellular carcinoma (HCC) is the fastest rising cause of cancer-related death in the United States; however, HCC incidence and mortality are not equally distributed among racial/ethnic groups. Our aim was to characterize the direction and magnitude of racial/ethnic disparities in overall survival and early tumor detection among patients with HCC.We searched MEDLINE, EMBASE and Cochrane […]
• Risk of serious infections with vedolizumab versus tumor necrosis factor antagonists in patients with inflammatory bowel disease.2nd January 2021
  The risk of serious infections associated with vedolizumab in patients with inflammatory bowel disease (IBD) is uncertain. We assessed the risk of serious infections associated with use of vedolizumab versus anti-TNF in patients with IBD, according to IBD subtype and previous exposure to anti-TNF.Based on two U.S. nationwide commercial insurance databases and the French nationwide […]
• Main Duct Thresholds For Malignancy Are Different In Intraductal Papillary Mucinous Neoplasms Of The Pancreatic Head And Body-Tail.1st January 2021
  The risk of malignancy is uncertain for of intraductal papillary mucinous neoplasms (IPMNs) with main pancreatic duct (MPD) of 5-9 mm. No study has correlated MPD size and malignancy considering the anatomic site of the gland (head versus body-tail). Our aim was to analyze the significance of MPD in pancreatic head/body-tail as a predictor of […]
• Patient Satisfaction of Propofol Versus Midazolam and Fentanyl Sedation During Colonoscopy in Inflammatory Bowel Disease.29th December 2020
  Colonoscopy is essential for optimal management of inflammatory bowel disease (IBD). However, many patients opt out due to unpleasantness related to this procedure. We investigated if Nurse Administered Propofol Sedation (NAPS) would improve patient satisfaction and attitude towards future colonoscopies.Randomized clinical trial of deep sedation with NAPS (n=63) versus moderate midazolam and fentanyl sedation (n=67). […]
• RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease.28th December 2020
  Receptor-interacting protein kinase 3 (RIPK3) is a key player in necroptosis execution and an emerging metabolic regulator, whose contribution to non-alcoholic fatty liver disease (NAFLD) is controversial. We aimed to clarify the impact of RIPK3 signalling in the pathogenesis of human and experimental NAFLD.RIPK3 levels were evaluated in two large independent cohorts of patients with […]
• NATURAL HISTORY OF PERIANAL CROHN’S DISEASE: LONG-TERM FOLLOW-UP OF A POPULATION-BASED COHORT.28th December 2020
  The natural history of perianal Crohn’s disease (PCD) remains poorly described and is mainly based on retrospective studies from referral centres. The aim of this study was to assess the incidence, outcomes and predictors of the onset of PCD.All incident cases of patients diagnosed with possible CD were prospectively registered from 1994 to 1997 in […]
• Racial and ethnic disparities in germline genetic testing of patients with young-onset colorectal cancer.28th December 2020
  Up to 20% of younger patients (age <50 years) diagnosed with colorectal cancer (CRC) have germline mutations in cancer susceptibility genes. Germline genetic testing may guide clinical management and facilitate earlier intervention in affected relatives. Few studies have characterized differences in genetic testing by race/ethnicity.We identified young adults (age 18-49 years) diagnosed with CRC between […]
• Stoma formation in Crohn’s Disease and the likelihood of antidepressant use: a population-based cohort study.28th December 2020
  The impact of a temporary or permanent stoma on mental health in Crohn’s Disease (CD) is unknown.To examine the association between intestinal surgery and stoma formation and subsequent antidepressant medication (ADM) use.Using the Clinical Practice Research Datalink, we identified individuals with CD who underwent intestinal surgery between 1998-2018. We excluded individuals with a prescription for […]
• Impact of HIV infection on the course of inflammatory bowel disease and drug safety profile: a multicenter GETAID study.28th December 2020
  Inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), and human immunodeficiency virus (HIV) both impact innate and adaptive immunity in the intestinal mucosa. As it is a rare situation, the intersection between HIV and IBD remains unclear, especially the impact of HIV infection on the course of IBD, and the drug […]
• Hepatobiliary acid-base homeostasis: Insights from analogous secretory epithelia.21st December 2020
  Many epithelia secrete bicarbonate-rich fluid to generate flow, alter viscosity, control pH and potentially protect luminal and intracellular structures from chemical stress. Bicarbonate is a key component of human bile and impaired biliary bicarbonate secretion is associated with liver damage. Major efforts have been undertaken to gain insight into acid-base homeostasis in cholangiocytes and more […]
• Hepatocyte-specific NRF2 activation controls fibrogenesis and carcinogenesis in steatohepatitis.21st December 2020
  In chronic liver diseases, inflammation induces oxidative stress and thus may contribute to the progression of liver injury, fibrosis, and carcinogenesis. The KEAP1/NRF2 axis is a major regulator of cellular redox balance. In the present study, we investigated whether the KEAP1/NRF2 system is involved in liver disease progression in humans and mice.The clinical relevance of […]
• Validation of the Short Form Esophageal Hypervigilance and Anxiety Scale.21st December 2020
  Esophageal hypervigilance and anxiety are emerging as important drivers of dysphagia symptoms and reduced quality of life across esophageal diagnoses. The esophageal hypervigilance and anxiety scale (EHAS) is a validated measure of these cognitive-affective processes. However, its length may preclude it from use in clinical practice. We aimed to create a short form version of […]
• Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.21st December 2020
  An international expert panel proposed a new definition for metabolic dysfunction-associated fatty liver disease (MAFLD) as a name change from nonalcoholic fatty liver disease (NAFLD). The clinical impact of this change on the assessment of cardiovascular disease (CVD) risk is yet unknown. We evaluated the prevalence of fatty liver disease (FLD) and the associated CVD […]
• Superiority of Self-Expandable Metallic Stents (SEMS) Over Plastic Stents (PS) in Treatment of Malignant Distal Biliary Strictures.21st December 2020
  Treatment of malignant biliary strictures with endoscopic retrograde cholangiopancreatography (ERCP) guided stent placement is highly effective. Our objective was to compare the efficacy and adverse outcomes between plastic stents (PS) and self-expandable metallic stents (SEMS).A cohort study was performed of all consecutive patients who underwent ERCP with stent placement for the management of malignant biliary […]
• Exome-wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated with Fatty Liver Disease.21st December 2020
  Fatty liver disease (FLD) is a growing epidemic that is expected to be the leading cause of end-stage liver disease within the next decade. Both environmental and genetic factors contribute to the susceptibility of FLD. Several genetic variants contributing to FLD have been identified in exome-wide association studies. However, there is still a missing hereditability […]
• Hepatic stellate cells in hepatocellular carcinoma promote tumor growth via growth differentiation factor 15 production.21st December 2020
  Although the tumor microenvironment plays an important role in tumor growth, it is not fully understood what role hepatic stellate cells (HSCs) play in the hepatocellular carcinoma (HCC) microenvironment.A high-fat-diet following streptozotocin was administered to HSC-specific Atg7-deficient (GFAP-Atg7KO) or GDF15-dificient (GFAP-GDF15KO) mice. LX-2 cells, a human HSC cell line, were cultured with human hepatoma cells.In […]
• T cell receptor repertoires within liver allografts are different to those in the peripheral blood.21st December 2020
  T cells are the main mediators of allogeneic immune responses. Specific T cell clones can be tracked by their unique T cell receptor (TCR), but specificity and function remain elusive and have not been investigated in human liver biopsies thus far.TCR repertoire analysis of CD4+, CD8+ and regulatory T cells of the peripheral blood and […]
• Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.18th December 2020
  Telomerase activation is the earliest event in hepatocellular carcinoma (HCC) development. We aimed to elucidate telomere length (TL) control during liver carcinogenesis.TL was measured in the tumor and non-tumor liver tissues of 1,502 patients (978 with HCC) and integrated with TERT alterations and expression, clinical and molecular features of HCC analyzed by genome, exome, targeted […]
• Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials.18th December 2020
  In patients with Crohn’s disease and ulcerative colitis, poor correlation between symptoms and active luminal inflammation has been well established. As a result, the field has moved towards the use of endoscopic assessment to evaluate inflammatory activity. Numerous endoscopic indices have been used for this purpose although none are completely validated. The Simple Endoscopic Score […]
• Determinants And Trends Of Adherence To A Gluten-Free Diet In Adult Celiac Patients On A Long-Term Follow-Up (2000-2020).18th December 2020
  Data on factors governing long-term adherence to a gluten-free diet (GFD) in celiac disease (CD) are scarce. We aimed to determine trends and clinical predictors of long-term GFD adherence in adult CD.Initial and long-term (>3 years) GFD adherence, clinical characteristics at baseline and follow-up were collected retrospectively from celiac patients followed-up over 20 years (2000-2020). […]
• Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target.18th December 2020
  Telomerase activation is the earliest event in hepatocellular carcinoma (HCC) development. We aimed to elucidate telomere length (TL) control during liver carcinogenesis.TL was measured in the tumor and non-tumor liver tissues of 1,502 patients (978 with HCC) and integrated with TERT alterations and expression, clinical and molecular features of HCC analyzed by genome, exome, targeted […]
• Endoscopic Assessment of Inflammatory Bowel Disease Activity in Clinical Trials.18th December 2020
  In patients with Crohn’s disease and ulcerative colitis, poor correlation between symptoms and active luminal inflammation has been well established. As a result, the field has moved towards the use of endoscopic assessment to evaluate inflammatory activity. Numerous endoscopic indices have been used for this purpose although none are completely validated. The Simple Endoscopic Score […]
• Determinants And Trends Of Adherence To A Gluten-Free Diet In Adult Celiac Patients On A Long-Term Follow-Up (2000-2020).18th December 2020
  Data on factors governing long-term adherence to a gluten-free diet (GFD) in celiac disease (CD) are scarce. We aimed to determine trends and clinical predictors of long-term GFD adherence in adult CD.Initial and long-term (>3 years) GFD adherence, clinical characteristics at baseline and follow-up were collected retrospectively from celiac patients followed-up over 20 years (2000-2020). […]
• Identification of a novel long-acting 4′-modified nucleoside reverse transcriptase inhibitor against HBV.17th December 2020
  While certain nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) are efficacious in treating HBV infection, their effects are yet to be optimized and the emergence of NRTI-resistant HBVs remains to be a challenging issue since life-long medication is needed, making it crucial to develop agents that more profoundly suppress wild-type and drug-resistant HBVs and have a long-acting […]
• Primary biliary cholangitis: pathogenic mechanisms.17th December 2020
  Primary biliary cholangitis (PBC) is characterized by autoimmune damage of intrahepatic bile ducts associated with a loss of tolerance to mitochondrial antigens. PBC etiopathogenesis is intriguing because of different perplexing features, namely: a) although mitochondria are present in all cell types and tissues, the damage is mainly restricted to biliary epithelial cells (BECs); b) despite […]
• Autoimmune hepatitis: from immunopathogenesis to diagnostic and therapeutic innovation.14th December 2020
  To understand the pathogenesis of autoimmune hepatitis (AIH) and the accuracy of diagnosis and treatment options that have improved lately. We summarize the latest research.Concerning pathogenesis of AIH, different groups have identified pieces of the puzzle that fit together well: An altered microbiome in the gut results in a proinflammatory response in the liver. This […]
• INTEGRATED MULTI-OMICS REVEALS GLUCOSE USE REPROGRAMMING AND IDENTIFIES A NOVEL HEXOKINASE IN ALCOHOLIC HEPATITIS.14th December 2020
  We recently demonstrated that alcoholic hepatitis (AH) is characterized by de-differentiation of hepatocytes and loss of mature functions. Glucose metabolism is tightly regulated in healthy hepatocytes. We hypothesize that AH may lead to metabolic reprogramming of the liver, including dysregulation of glucose metabolism.We performed integrated metabolomic and transcriptomic analyses of liver tissue from patients with […]
• Association of genetic variation with cirrhosis: a multi-trait genome-wide association and gene-environment interaction study.14th December 2020
  In contrast to most other common diseases, few genetic variants have been identified that impact risk of cirrhosis. We aimed to identify new genetic variants that predispose to cirrhosis, to test whether such variants, aggregated into a polygenic score, enable genomic risk stratification and to test whether alcohol intake or body mass index interact with […]
• Genetic evidence that a gut commensal bacterium can cause colorectal cancer.14th December 2020
  Our gastrointestinal tract is colonized by trillions of microbes. There is growing recognition that commensal bacteria can promote the development of colorectal adenomas and cancer. For example, bacterial plaques are strongly associated with adenomas in familial adenomatous polyposis (Science 2018;359:592-597), and fusobacterium is associated with colorectal cancer liver metastasis.(Science 2017;358:1443-1448). View the full article @ […]
• PREDICTION OF SUSTAINED RESPONSE AFTER NUCLEO(S)TIDE ANALOGUE CESSATION USING HBSAG AND HBCRAG LEVELS – A MULTICENTER STUDY (CREATE).14th December 2020
  Predictors of successful nucleo(s)tide analogue (NA) therapy withdrawal remain elusive. We studied the relationship between end-of-treatment levels of hepatitis B core related antigen (HBcrAg) and surface antigen (HBsAg) and outcome after therapy cessation.Patients who discontinued NA therapy in centers in Asia and Europe were enrolled. HBcrAg and HBsAg were measured at treatment cessation, and associations […]
• Comorbidities Drive the Majority of Overall Mortality in Low-risk Mucinous Pancreatic Cysts under Surveillance.14th December 2020
  The Charlson Comorbidity Index (CACI) has been suggested as a tool to determine comorbidity burden and guide management for patients with mucinous pancreatic cysts (Intrapapillary Mucinous Neoplasms and Mucinous Cystic Neoplasms), but has not been studied well among “low-risk” mucinous pancreatic cysts i.e. without worrisome features (WF) and high-risk stigmata (HRS). This study sought to […]
• Population-based Screening for Hereditary Colorectal Cancer Variants in Japan.14th December 2020
  Colorectal cancer (CRC) is one of the most common cancers in the world. A small proportion of CRCs can be attributed to recognizable hereditary germline variants of known CRC susceptibility genes. To better understand cancer risk, it is necessary to explore the prevalence of hereditary CRC and pathogenic variants of multiple cancer-predisposing genes in non-European […]
• Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study.14th December 2020
  Radical surgery via total mesorectal excision might not be the optimal first-line treatment for early-stage rectal cancer. An organ-preserving strategy with selective total mesorectal excision could reduce the adverse effects of treatment without substantially compromising oncological outcomes. We investigated the feasibility of recruiting patients to a randomised trial comparing an organ-preserving strategy with total mesorectal […]
• Mechanisms of autoimmune hepatitis.14th December 2020
  Autoimmune hepatitis (AIH) is a chronic disease characterized by a lymphocyte infiltrate in the liver. For decades, nonspecific immunosuppression has been used to limit chronic liver inflammation. The high risk of relapse, the treatments side effects, and the significant number of refractory patients are the main clinical issues that require efforts to understand AIH immune […]
• Reticulon 3-mediated Chk2/p53 activation suppresses hepatocellular carcinogenesis and is blocked by hepatitis B virus.11th December 2020
  Dysfunction of endoplasmic reticulum (ER) proteins is closely related to homeostasis disturbance and malignant transformation of hepatocellular carcinoma (HCC). Reticulons (RTN) are a family of ER-resident proteins critical for maintaining ER function. Nevertheless, the precise roles of RTN in HCC remain largely unclear. The aim of the study is to examine the effect of reticulon […]
• Non-alcoholic fatty liver disease and risk of incident chronic kidney disease: an updated meta-analysis.11th December 2020
  Studies reported a significant association between non-alcoholic fatty liver disease (NAFLD) and increased risk of chronic kidney disease (CKD). However, whether this risk changes with increasing severity of NAFLD remains uncertain. We performed a meta-analysis of observational studies to quantify the magnitude of the association between NAFLD and risk of incident CKD.We systematically searched PubMed, […]
• Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease.11th December 2020
  The Baveno VI consensus proposed a dual liver stiffness (LS) by transient elastography threshold of <10 and >15 kPa for excluding and diagnosing compensated advanced chronic liver disease (cACLD), in the absence of other clinical signs. We validated these criteria in a real-world multicentre study.We included 5648 patients (mean age 51±13 years, 53% males) from […]
• HCC surveillance after SVR in patients with F3/F4 fibrosis.11th December 2020
  HCV eradication by antiviral treatment reduces but does not eliminate HCC risk. Patients with established cirrhosis require HCC surveillance “indefinitely” after sustained virologic response (SVR) because they appear to have a high risk of HCC even many years after SVR. Patients without established or known cirrhosis may still require surveillance after SVR if they have […]
• Long-Term Outcomes Following Multiply Recurrent Clostridioides Difficile Infection and Fecal Microbiota Transplantation.11th December 2020
  Fecal microbiota transplantation (FMT) is a commonly used therapy for multiply recurrent Clostridioides difficile (mrCDI). By altering the gut microbiota, there is the potential for FMT to impact the risk for cardiometabolic, intestinal or immune-mediated conditions. Likewise, the microbiota disturbance associated with mrCDI could potentially lead to these conditions. We aimed to assess the associations […]